A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer
An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer (HRPC) and Rising Prostate Specific Antigen (PSA) Levels Who Have Not Received Prior Chemotherapy
Sponsor: Ascenta Therapeutics
This PHASE1/PHASE2 trial investigates Hormone Refractory Prostate Cancer and is currently completed. Ascenta Therapeutics leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
First recorded
Dec 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ascenta Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .